fadrozole has been researched along with Cardiovascular Diseases in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hartmann, RW; Hu, Q; Yin, L | 3 |
| Engel, M; Hartmann, RW; Hu, Q; Pinto-Bazurco Mendieta, MA | 1 |
| Chinchilli, VM; Costa, LA; Demers, LM; Harvey, HA; Kopreski, MS; Lipton, A; Santen, RJ | 1 |
5 other study(ies) available for fadrozole and Cardiovascular Diseases
| Article | Year |
|---|---|
Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cytochrome P-450 CYP11B2; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Female; Humans; In Vitro Techniques; Liver; Quinolones; Solubility; Steroid 11-beta-Hydroxylase; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship | 2012 |
Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cytochrome P-450 CYP11B2; Female; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Quinolones; Risk Factors; Spectrometry, Mass, Electrospray Ionization | 2013 |
Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Cell Line; Cytochrome P-450 CYP11B2; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Humans; Male; Models, Molecular; Naphthalenes; Prostatic Neoplasms; Pyridines; Steroid 11-beta-Hydroxylase; Steroid 17-alpha-Hydroxylase | 2013 |
Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.
Topics: Aldosterone; Animals; Benzimidazoles; Cardiovascular Diseases; Cytochrome P-450 CYP11B2; Fadrozole; Humans; Indans; Indoles; Kidney Diseases; Mineralocorticoids; Naphthalenes; Quinolines; Receptors, Mineralocorticoid | 2014 |
Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antithrombin III; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol; Enzyme Inhibitors; Estrogen Antagonists; Fadrozole; Female; Fibrinogen; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Middle Aged; Postmenopause; Protein C; Protein S; Risk Factors; Triglycerides | 1999 |